Healthy person Minamata disease, Neuropathic pain
Conditions
Interventions
1) otDCS
otDCS involves applying both direct current stimulation (tDCS, 1mA for 20 minutes to the motor cortex) and alternating current stimulation (tACS, 10Hz, 2mA amplitude for 20 minutes to the mot
Sponsors
Nakamura Masaaki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Age at the time of informed consent: 40 years or older 2.Gender: No matter 3.No dementia, aphasia, psychiatric disorders, higher-level functional disorders, or suicidal tendencies. 4.After receiving a full explanation of the study and fully understanding it, participants have given written consent of their own free will. 5.No neuropathic diseases such as diabetic neuropathy.
Exclusion criteria
Exclusion criteria: 1.Individuals who met the eligibility criteria, but were deemed unsuitable for enrollment in the clinical study by the Contact for Sponsor. 2.Individuals with Diabetic Neuropathy. 3.Individuals who were unable to undergo a 3TMRI scan. 4.Pregnant or potentially pregnant women. 5.Individuals with any metal in the head, excluding the oral cavity. 6.Individuals with an implanted cardiac pacemaker or drug infusion pump. 7.Patients with a history of major cerebral infarction, significant head trauma, brain tumor, or epilepsy (owing to an increased risk of seizure induction). 8.Individuals with a history of syncope. 9.Individuals currently taking antibiotics(aminoglycosides). 10.Individuals with severe hearing impairment or tinnitus. (Check for hearing aids and ENT treatment if any.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PAF(Hz),Power Value: before and after (+0min, +20min, +40min) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.gamma activity, inhibition and rebound of SEF: before and after (+0min, +20min, +40min) Relative value of gamma-activity Rhythm of beta-band: frequency (Hz) and duration (ms) of beta-bursts for inhibition and rebound, respectively 2.Thalamic GABA/Glx ratio: before treatment 3.Safety The occurrence of adverse events due to the three stimulation methods performed will be evaluated. | — |
Contacts
Public ContactNobuko Tabata
National Institute for Minamata Disease
Outcome results
None listed